An Open-label, Randomized, Active Controlled, Parallel Comparison Study of the Safety and Efficacy of REP 2139-Mg in Combination With Pegasys® and Viread® and REP 2165-Mg in Combination With Pegasys® and Viread® in Patients With HBeAg Negative Chronic Hepatitis B
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Nov 2017
At a glance
- Drugs REP 2139-Ca (Primary) ; Interferon alpha-2a; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors REPLICor
- 28 Nov 2017 According to a Replicor media release, data will be presented as oral presentation at the 2017 HEP DART meeting.
- 23 Oct 2017 According to a Replicor media release, first interim follow-up data from this study presented at the 2017 meeting of the American Association for the Study of Liver Disease (AASLD).
- 23 Oct 2017 Results published in the Replicor Media Release